Peginterferon still has a place in the treatment of hepatitis C caused by genotype 3 virus

Página do item simplificado
dc.citation.volume59
dc.contributor.authorGrando, Aline Vitali
dc.contributor.authorAbrao Ferreira, Paulo Roberto [UNIFESP]
dc.contributor.authorPessoa, Mario Guimaraes
dc.contributor.authorde Campos Mazo, Daniel Ferraz
dc.contributor.authorBrandao-Mello, Carlos Eduardo
dc.contributor.authorReuter, Tania
dc.contributor.authorCandolo Martinelli, Ana de Lourdes
dc.contributor.authorGonzalez, Mario Peribanez
dc.contributor.authorSeixas-Santos Nastri, Ana Catharina
dc.contributor.authorCampos, Aleia Faustina
dc.contributor.authorBanks Ferreira Lopes, Max Igor
dc.contributor.authorUrbaez Brito, Jose David
dc.contributor.authorMendes-Correa, Maria Cassia
dc.coverageSao Paulo
dc.date.accessioned2020-07-17T14:03:30Z
dc.date.available2020-07-17T14:03:30Z
dc.date.issued2017
dc.description.abstractDespite recent advances in therapy for chronic hepatitis C (CHC), the disease caused by genotype 3 virus (GEN3) is still considered a treatment challenge in certain patient subgroups. The aim of this retrospective study was to evaluate the effectiveness and safety of the peginterferon (Peg-IFN) and ribavirin (RBV) combination treatment for GEN3/CHC patients, and to evaluate sustained virological response (SVR) indicators and early treatment interruption due to serious adverse events (SAE). This was a retrospective observational study of GEN3/CHC patients, co-infected or not by HIV and treated with Peg-IFN/RBV in nine Brazilian healthcare centers. The study sample included 184 GEN3/CHC patientsen
dc.description.abstract70 (38%) were co-infected with HIV. The overall SVR rate was 57.1% (95% CI 50-64). Among co-infected and mono-infected patients, the SVR rate was 51.4% (36/70) and 60.5% (69/114), respectively (p=0.241). Thirty-four (18.5%) patients experienced SAE and interrupted treatment. SVR was negatively associated with the use of Peg-IFN alpha 2b (PR 0.75en
dc.description.abstract95% CI 0.58-0.99en
dc.description.abstractp=0.045) and to early treatment interruption due to SAE (PR 0.36en
dc.description.abstract95% CI 0.20-0.68en
dc.description.abstractp=0.001). Early treatment interruption due to SAE was associated with age (PR 1.06en
dc.description.abstract95% CI 1.02-1.10en
dc.description.abstractp<0.001) and occurrence of liver cirrhosis (PR 2.06en
dc.description.abstract95% CI 1.11-3.83en
dc.description.abstractp=0.022). In conclusion, Peg-IFN/RBV might represent an adequate treatment option, mainly in young patients without advanced liver disease or when the use of direct-action drugs is limited to specific patient groups.en
dc.description.affiliationUniv Sul Santa Catarina, Fac Med, Dept Ciencias Biol & Saude & Ciencias Sociais Apl, Disciplina Doencas Infecciosas, Av Pedra Branca 25, BR-88137270 Palhoca, SC, Brazil
dc.description.affiliationUniv Fed Sao Paulo, Disciplina Infectol, Sao Paulo, SP, Brazil
dc.description.affiliationUniv Sao Paulo, Fac Med, Div Gastroenterol & Hepatol, Sao Paulo, SP, Brazil
dc.description.affiliationUniv Fed Estado Rio de Janeiro, Dept Clin Med, Disciplina Gastroenterol, Rio De Janeiro, RJ, Brazil
dc.description.affiliationUniv Fed Espirito Santo, Serv Infectol, Vitoria, ES, Spain
dc.description.affiliationUniv Sao Paulo, Fac Med Ribeirao Preto, Div Gastroenterol, Ribeirao Preto, SP, Brazil
dc.description.affiliationInst Infectol Emilio Ribas, Sao Paulo, SP, Brazil
dc.description.affiliationUniv Sao Paulo, Fac Med, Dept Doencas Infecciosas & Parasitarias, Sao Paulo, SP, Brazil
dc.description.affiliationSecretaria Estadual Saude, Unidade Mista Saude, Unimista 508 509, Brasilia, DF, Brazil
dc.description.affiliationUniv Sao Paulo, Inst Med Trop Sao Paulo, Lab Virol, LIM 52, Sao Paulo, SP, Brazil
dc.description.affiliationUnifespUniv Fed Sao Paulo, Disciplina Infectol, Sao Paulo, SP, Brazil
dc.description.sourceWeb of Science
dc.format.extent-
dc.identifierhttp://dx.doi.org/10.1590/S1678-9946201759067
dc.identifier.citationRevista Do Instituto De Medicina Tropical De Sao Paulo. Sao Paulo, v. 59, p. -, 2017.
dc.identifier.doi10.1590/S1678-9946201759067
dc.identifier.fileS0036-46652017005000239.pdf
dc.identifier.issn0036-4665
dc.identifier.scieloS0036-46652017005000239
dc.identifier.urihttps://repositorio.unifesp.br/handle/11600/55442
dc.identifier.wosWOS:000414712400001
dc.language.isoeng
dc.publisherInst Medicina Tropical Sao Paulo
dc.relation.ispartofRevista Do Instituto De Medicina Tropical De Sao Paulo
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subjectHepatitis Cen
dc.subjectChronic hepatitis Cen
dc.subjectCoinfection HCV-HIVen
dc.subjectInterferonsen
dc.subjectRibavirinen
dc.subjectHCV genotypesen
dc.titlePeginterferon still has a place in the treatment of hepatitis C caused by genotype 3 virusen
dc.typeinfo:eu-repo/semantics/article
Arquivos
Pacote Original
Agora exibindo 1 - 1 de 1
Imagem de Miniatura
Nome:
S0036-46652017005000239.pdf
Tamanho:
307.91 KB
Formato:
Adobe Portable Document Format
Descrição:
Baixar
Coleções
EPM - Outras produções